Ophthalmic-focused biopharmaceutical firm Sirion Therapeutics has reported positive preliminary results from its Phase III difluprednate program evaluating the steroid's potential to rapidly resolve inflammation in the eye following ocular surgery.

U.S. firm Sirion Therapeutics said Monday it has received orphan drug status for its ophthalmic drug for acute herpetic keratitis. The company said the U.S.